Abstract

Safe Cytotoxic Drug Preparation Using a Closed-system Transfer Device: Technical and Practical Evaluation of a New Device (Vialshield/Texium) Comparatively to a Reference One (Phaseal)

Author(s): Garrigue Philippe, Montana Marc, Ventre Christophe, Savry Amadine, Gauthier-Villano Laurence, Pisano Pascale, Pourroy Bertrand

Issue: Mar/Apr 2016 - Volume 20, Number 2

Page(s): 148-154

Download in electronic PDF format for $75
  • Safe Cytotoxic Drug Preparation Using a Closed-system Transfer Device: Technical and Practical Evaluation of a New Device (Vialshield/Texium) Comparatively to a Reference One (Phaseal) Page 1
  • Safe Cytotoxic Drug Preparation Using a Closed-system Transfer Device: Technical and Practical Evaluation of a New Device (Vialshield/Texium) Comparatively to a Reference One (Phaseal) Page 2
  • Safe Cytotoxic Drug Preparation Using a Closed-system Transfer Device: Technical and Practical Evaluation of a New Device (Vialshield/Texium) Comparatively to a Reference One (Phaseal) Page 3
  • Safe Cytotoxic Drug Preparation Using a Closed-system Transfer Device: Technical and Practical Evaluation of a New Device (Vialshield/Texium) Comparatively to a Reference One (Phaseal) Page 4
  • Safe Cytotoxic Drug Preparation Using a Closed-system Transfer Device: Technical and Practical Evaluation of a New Device (Vialshield/Texium) Comparatively to a Reference One (Phaseal) Page 5
  • Safe Cytotoxic Drug Preparation Using a Closed-system Transfer Device: Technical and Practical Evaluation of a New Device (Vialshield/Texium) Comparatively to a Reference One (Phaseal) Page 6
  • Safe Cytotoxic Drug Preparation Using a Closed-system Transfer Device: Technical and Practical Evaluation of a New Device (Vialshield/Texium) Comparatively to a Reference One (Phaseal) Page 7

Abstract

Closed-system transfer devices enhance the drug handlers’ protection against hazardous drugs exposure by prohibiting the escape of liquid or vapor from the system. PhaSeal (Becton Dickinson), a reference closed-system transfer device, includes a vial protector with an expansion chamber, and an injector with an enclosed needle. VialShield (CareFusion) is another more recent closed-system transfer device including an expansion chamber and a non-return valve, designed to be used in association with Texium (CareFusion), a closed, needlefree male luer with its preassembled syringe. Evaluation of VialShield/Texium was done comparatively to a classic spike device (Spike Swan, Codan) and PhaSeal. Evaluation methods consisted in practical evaluation by pharmacy technicians (evaluation of ease to use by nine operators in practical conditions during a complete week of production), microbiological safety performance (by Media Fill Test), and leakage assessment (fluorescein, titanium tetrachloride smoke, and radioactive tracer). Results showed that 100% of those operators evaluated would be ready to use VialShield/Texium for daily use, whereas only 75% of them would be ready to use PhaSeal. The use of PhaSeal and VialShield/Texium increased the duration of preparations compared to Spike Swan. No microbiological growth was observed with any of the three devices. A leakage of smoke was observed only with Spike Swan. Fluorescein leakage assessment confirmed that PhaSeal is a performing closed system with a dry connection. Spike Swan showed fluorescein leaks. Fluorescein drops were visible on the connection sites of the VialShield/Texium. Nevertheless, no fluorescein was found on compress after connections swapping. Transfer performance, assessed using technetium-99m, was 98.1 ± 1.4%, 97.9 ± 1.1% and 97.0 ± 1.3% and dead volume of the devices, were 1.0 ± 0.8%, 1.7 ± 0.6%, and 3.0 ± 1.1% for Spike Swan, PhaSeal, and VialShield/Texium, respectively. VialShield/Texium appeared as a very interesting device with performances close to PhaSeal (except dry connection), with a higher satisfaction assessment from the operators.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Mar/Apr 2016
Pg. 148-154
Sep/Oct 2012
Pg. 431-433
Jan/Feb 2022
Pg. 72-79
Nov/Dec 2021
Pg. 515-522
Sep/Oct 2022
Pg. 358-362
Jan/Feb 2020
Pg. 30-36
Author(s): Dillon L R
Mar/Apr 2023
Pg. 154-159
Jul/Aug 2023
Pg. 340-346
Nov/Dec 2019
Pg. 454-461
Mar/Apr 2018
Pg. 108-121
Mar/Apr 2013
Pg. 100-110
Jul/Aug 2000
Pg. 261-263
Author(s): Lau Kellie
Sep/Oct 2017
Pg. 356
Author(s): Allen Loyd V Jr
Jan/Feb 2017
Pg. 47-56
Author(s): Akers Michael J
Mar/Apr 2014
Pg. 94-99
Author(s): Marks Zach
Jan/Feb 2007
Pg. 50-51
Author(s): Allen Loyd V Jr
Nov/Dec 2006
Pg. 446-448
Author(s): Allen Loyd V Jr
Nov/Dec 2012
Pg. 456-460
Author(s): Lyon Joanna
May/Jun 2019
Pg. 182-186
Author(s): Dillon L Rad
Jul/Aug 2011
Pg. 308-315
Author(s): Allen Loyd V Jr